Skip to main content

Sellers Robert W.A.'s Form 4 filing

Edwards Lifesciences Corp (EW) · filed Feb 12, 2024

Accession no.
0001225208-24-001867
Filed
Feb 12, 2024
Trade date
Feb 12, 2024
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.06M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sellers Robert W.A.CIK 0001600739Officer (SVP, Corporate Controller)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 12, 2024Common StockMOption exerciseAcquired+12,210$36.75+$448,717.525,297.18Direct
Feb 12, 2024Common StockSSaleDisposed−12,210$87.00−$1,062,27013,087.18Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 12, 2024Common StockMOption exerciseDisposed−12,210$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Read the full filing on SEC EDGAR (opens in a new tab)